Crescent Capital Bdc Stock Earnings Reports

Crescent Capital BDC (CCAP) reported Q1 2026 results in a challenging credit-market backdrop with concentrated stress in certain portfolio pockets (notably select health care investments). Key financials and actions: net investment income (NII) was $0.38 per share (reported $0.42 after a voluntary $0.04 per share incentive fee waiver); NAV declined to $18.27 from $19.10 driven ~65% by market repricing and ~35% by credit-specific marks; investment portfolio fair value ~ $1.6 billion; net leverage 1.3x (slightly above 1.1–1.3x target, expected to normalize as realizations occur); liquidity of ~$206 million available capacity plus $27 million cash. Management announced structural changes: permanent fee reductions (base management fee from 1.25% to 1.0%; incentive fee from 17.5% to 15% effective April 1, 2026), reset of the quarterly base dividend from $0.42 to $0.34, plus three special $0.03 quarterly dividends in 2026 to return spillover income. Portfolio: ~86% of positions rated 1 or 2; weighted average interest coverage ~2.2x; nonaccruals rose (5 new nonaccruals concentrated in 4 health care investments), representing 5.7% of cost and 3.6% of fair value of debt investments. New originations: $115 million gross deployed (14 new platforms at ~500 bps weighted-average spread; Crescent led 93% of deals). Management emphasizes concentrated, actively managed credit issues, conservative valuation of watch list, first-lien orientation of stressed positions, and that the Sun Life acquisition of Crescent’s adviser aligns long-term capital and support. Guidance/positioning: expect continued selective deployment into higher-spread opportunities, conservative new position sizing, and that the fee/dividend changes improve consistency of earnings and shareholder alignment.